Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer

Sponsor
Hellenic Oncology Research Group
Study ID
NCT00694200
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Vinorelbine — DRUG
    Vinorelbine per os 50 mg 3 times a week
  • Bevacizumab — DRUG
    Bevacizumab 10 mg/kg IV every 14 days

Study Details

To evaluate the efficacy of metronomic oral vinorelbine taken three times a week without break plus bevacizumab as salvage treatment in patients with metastatic breast cancer.

Key Dates

Start date
Apr 30, 2008
Status verified
May 2015
Primary completion
Dec 31, 2009
Completion
Dec 31, 2009

Study Design

Enrollment
13 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Vinorelbine metronomic + bevacizumab

Primary Outcome Measure

Response rate [ Time Frame: Objective responses confirmed by CT or MRI (on 3rd and 6th cycle) ]

Related Studies